Goldline Pharmaceutical
UPCOMINGIPO Date: 12 May - 14 May 2026
Listing Date: 19 May 2026
Price Range
₹41 to ₹43
Issue Size
12 Cr
Min Investment
₹1,23,000
Lot Size
3000 Shares
Schedule of Goldline Pharmaceutical
Issue open date
12 May 2026
Issue close date
14 May 2026
UPI mandate deadline
14 May 2026 (5 PM)
Allotment finalization
15 May 2026
Share credit
18 May 2026
Listing date
19 May 2026
Mandate end date
29 May 2026
Issue size
| Funds Raised in the IPO | Amount |
|---|---|
| Overall | 12 Cr |
| Fresh Issue | 11 Cr |
| Offer for Sale | 0 Cr |
Allotment DetailsNew
| Allotment Timeline | Details |
|---|---|
| Allotment Date | 15 May 2026 |
| Allotment Link | {Link} |
Grey Market PremiumNew
Grey Market Premium (GMP) is the premium at which the shares are traded in the grey market. It gives a fair idea about the listing price of the IPO shares. The GMP can be positive or negative based on the demand and supply of the shares in the grey market.
| Date | Ipo Price | GMP | Estimated Listing Price |
|---|---|---|---|
| 9 May 2026 | ₹43 | ₹3 | ₹46 (8%) |
| 8 May 2026 | ₹43 | ₹3 | ₹46 (7%) |
| 7 May 2026 | ₹43 | ₹0 | ₹43 (0%) |
Performance Goldline Pharmaceutical
| Issue Price | Listing Gain | Current Market Price | P/L |
|---|---|---|---|
| ₹41 to ₹43 | .... | .... | .... |
About Goldline Pharmaceutical
Goldline Pharmaceutical Ltd. is an Indian pharmaceutical marketing company operating under the “Goldline” brand. The company offers a diversified portfolio of medicines and healthcare products across multiple therapeutic segments including cardiology, pediatrics, orthopedics, gastroenterology, critical care, and wellness support. Rather than manufacturing products directly, the company follows an asset-light model by partnering with third-party manufacturers for production while focusing on branding, distribution, and market expansion. Goldline supplies its products through a distributor network across several Indian states including Maharashtra, Bihar, Tamil Nadu, Odisha, Jharkhand, Rajasthan, and Madhya Pradesh. The company also supports hospitals and healthcare providers through procurement and medical supply services.
| Founded in | 2017 |
| Managing director | Mr. Santosh Kumar |
| Parent organization |
Financial Overview
Strengths
- Asset-light business model reduces manufacturing overhead and capital expenditure.
- Diversified product portfolio across multiple therapeutic categories lowers dependence on a single segment.
- Strong distribution and supplier network with partnerships involving multiple manufacturers and distributors.
- Scalable operations allowing expansion into new geographies and healthcare segments efficiently.
Risks
- Dependence on third-party manufacturers may impact supply consistency and quality control.
- Highly competitive pharmaceutical market with pressure from established pharma brands and generic drug companies.
- Regulatory risks related to drug approvals, compliance, and healthcare regulations.
- Geographic concentration risk since operations are mainly focused on selected Indian states.
Subscription Figures
| Category | Subscription (No. of times) |
|---|---|
| Qualified Institutional Buyers (QIBs) | N/A |
| Non-Institutional Investors (NIIs) | N/A |
| Retail Individual Investors (RIIs) | N/A |
| Employee | N/A |
| Total | N/A |